Review
Oncology
Omar Fahmy, Maxim Kochergin, Anastasios D. Asimakopoulos, Georgios Gakis
Summary: Extended pelvic lymph node dissection has been a standard practice during radical cystectomy for patients with muscle invasive bladder cancer. However, based on recent studies, standard pelvic lymph node dissection up to the level of iliac bifurcation is sufficient and there is no additional oncologic benefit from extending the dissection above this level.
SEMINARS IN ONCOLOGY
(2023)
Review
Oncology
Chengyu You, Qingchao Li, Yongjin Yang, Liangliang Qing, Shuai Liu, Yanan Wang, Zhilong Dong
Summary: This study compared the perioperative and oncologic outcomes of extraperitoneal radical cystectomy (EPRC) and transperitoneal radical cystectomy (TPRC). The results showed that although EPRC had a higher incidence of lymphoceles, it had similar oncologic outcomes and fewer early complications, particularly in terms of postoperative gastrointestinal complications and ileus.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Khatereh Aminoltejari, Amanda E. Hird, Zachary Klaassen, Raj Satkunasivam, Girish S. Kulkarni, Amy N. Luckenbaugh, Aaron A. Laviana, Christopher J. D. Wallis, Roderick Clark
Summary: This study compared robotic assisted radical cystectomy (RARC) with open radical cystectomy (ORC) through systematic reviews. The findings show that RARC has advantages in terms of less blood loss, lower transfusion rates, and longer operative time compared to ORC. However, there is limited evidence on differences in hospital length of stay, complication rates, oncologic outcomes, and QOL between the two approaches. Further prospective studies are needed to evaluate the impact of diversion type, technique, and recovery pathways on patient outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Junhao Long, Li Wang, Ni Dong, Xiaoli Bai, Siyu Chen, Shujun Sun, Huageng Liang, Yun Lin
Summary: The meta-analysis shows that robotic-assisted radical cystectomy (RARC) is as safe and effective as laparoscopic radical cystectomy (LRC) in the treatment of bladder cancer. Patients who undergo RARC experience less blood loss and fewer long-term complications related to surgery compared to LRC. RARC should be considered as a viable alternative to LRC. However, further high-quality, larger sample, multi-centric, long-term follow-up randomized controlled trials (RCTs) are still needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2022)
Review
Surgery
Naichun Zhou, Fengyan Tian, Yongjie Feng, Keyuan Zhao, Long Chen, Ruixin Fan, Wei Lu, Chaohui Gu
Summary: In comparison with open radical cystectomy, intracorporeal robot-assisted radical cystectomy was associated with lower estimated blood loss, lower blood transfusion rates, and lower major postoperative complication rates. However, it had a longer operative time and showed no significant difference in terms of other outcomes.
INTERNATIONAL JOURNAL OF SURGERY
(2021)
Article
Urology & Nephrology
Francesco Soria, Peter C. Black, Adrian S. Fairey, Michael S. Cookson, Evan Y. Yu, Wassim Kassouf, Marc A. Dall'Era, Srikala S. Sridhar, John S. McGrath, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Siamak Daneshmand, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Jay B. Shah, Bas W. van Rhijn, Philippe E. Spiess, Shahrokh F. Shariat, Paolo Gontero
Summary: In patients with cT2N0 bladder cancer and no preoperative hydronephrosis, neoadjuvant chemotherapy (NAC) increased the rate of pathological complete response and downstaging, showing a positive impact on overall survival.
Review
Medicine, General & Internal
Lin Dong, Feng Xiaoli, Lu Ya, Wu Dan, Hu Jingwen, Liu Xun, Chen Shujin, Zhou Zhijun, Zhang Tian, Luo Hao, Yi Chuanlang, Chen Guangrong, Wang Xiaodong, Luo Gewen, Zhang Yichi, Cao Pei, Liu Yang, Wang Youliang
Summary: The study compared the long-term oncologic outcomes of ORC, LRC, and RARC for bladder cancer and found no significant differences between the three surgical approaches. However, probabilistic analysis ranking indicated that LRC may be a better surgical approach.
Review
Oncology
Xiaozhe Su, Caitao Dong, Wenbiao Liao, Wentao Liu
Summary: The study found that radical cystectomy (RC) has better treatment outcomes in terms of overall survival and cancer-specific survival compared to trimodal therapy (TMT). Unless patients cannot tolerate or have a strong desire to preserve the bladder, RC should be chosen over TMT in treatment.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Carl J. Wijburg, Charlotte T. J. Michels, Gerjon Hannink, Janneke P. C. Grutters, Maroeska M. Rovers, J. Alfred Witjes
Summary: This study did not find significant differences in complications and health-related quality of life between robot-assisted radical cystectomy and open radical cystectomy. However, there were some differences in secondary outcomes, with the main limitation being residual confounding.
Article
Surgery
Wenlong Zhong, Kun Xia, Libo Liu, Sida Cheng, Peng Hong, Wang He, Wen Dong, Hao Liu, Yiming Lai, Han Hao, Cheng Liu, Hongxian Zhang, Xinfei Li, Guangpu Ding, Xuesong Li, Lulin Ma, Liqun Zhou, Tianxin Lin, Jian Huang
Summary: This study compared the long-term oncological outcomes of pelvic organ preserving-radical cystectomy (POPRC) and standard radical cystectomy (SRC) in female patients with bladder cancer. The results showed no significant difference in overall survival between the two surgical methods.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Oncology
Vishnukamal Golla, Yong Shan, Elias J. Farran, Courtney A. Stewart, Kevin Vu, Alexander Yu, Ali Raza Khaki, Divya Ahuja Parikh, Todd A. Swanson, Kirk A. Keegan, Ashish M. Kamat, Douglas S. Tyler, Stephen J. Freedland, Stephen B. Williams
Summary: This study compared the 2- and 5-year healthcare costs of trimodal therapy (TMT) and radical cystectomy (RC) for patients with muscle-invasive bladder cancer. The results showed that TMT had higher costs, particularly in outpatient settings.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Multidisciplinary Sciences
Weishen Wang, Wenhui Lou, Zhiwei Xu, Haoda Chen, Ziyun Shen, Xiaxing Deng, Chenghong Peng, Yingbin Liu, Baiyong Shen
Summary: This multicenter randomized controlled study found that extended lymphadenectomy during pancreatoduodenectomy did not improve long-term survival in patients with pancreatic ductal adenocarcinoma (PDAC). However, the stage migration caused by extended lymphadenectomy contributed to precise tumor staging.
JOURNAL OF ADVANCED RESEARCH
(2023)
Article
Oncology
John P. Stein, Gary Lieskovsky, Richard Cote, Susan Groshen, An-Chen Feng, Stuart Boyd, Eila Skinner, Bernard Bocher, Duriayai Thangathurai, Maged Mikhail, Derek Raghavan, Donald G. Skinner
Summary: This study evaluated the long-term clinical outcomes of patients with invasive bladder cancer who underwent radical cystectomy and pelvic lymph node dissection. The results showed that the primary bladder tumor stage and lymph node status were associated with the prognosis of patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
P. Sparwasser, L. Frey, N. D. Fischer, A. Thomas, R. Dotzauer, C. Surcel, M. P. Brandt, R. Mager, T. Hoefner, A. Haferkamp, I. Tsaur
Summary: This study aimed to compare robot-assisted transperitoneal nephroureterectomy (TRNU) with robot-assisted retroperitoneal nephroureterectomy with bladder cuff (RRNU). The results showed no significant difference in intra- and postoperative complications between the two surgical techniques, but RRNU had significantly shorter surgery time and length of stay. RRNU is a safe and feasible treatment option, especially for patients with major previous abdominal surgery.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Hongquan Liu, Zhongbao Zhou, Huibao Yao, Qiancheng Mao, Yongli Chu, Yuanshan Cui, Jitao Wu
Summary: Even though there isn't enough clinical evidence to demonstrate that robot-assisted radical cystectomy (RARC) is preferable to open radical cystectomy (ORC), RARC has become a widely used alternative. The study compared the oncologic, pathological, perioperative, and complication-related outcomes as well as health-related quality of life (QOL) between RARC and ORC.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)